Debarati Shome
I work with pharmaceutical and biotech partners to identify opportunities and shape tailored research collaborations addressing drug development challenges. As a liaison between industry partners and TNO’s scientific experts, I align research needs with our in vitro and ex vivo preclinical ADME capabilities, bringing together the right expertise to support informed decisions on drug candidates across multiple modalities.
I work with pharmaceutical and biotech companies to translate drug development challenges into tailored research collaborations, connecting industry needs with TNO’s preclinical ADME expertise.
Working closely with industry partners and TNO’s scientific teams, I identify opportunities, build partnerships, and bring together the right expertise to develop tailored research solutions. My focus spans intestinal absorption, oral drug development, drug metabolism, and drug–drug interactions, drawing on our in vitro and ex vivo capabilities, including InTESTine, microphysiological systems such as organ-on-chip platforms, and whole-organ perfusion models.
I also bring industry insights into discussions on emerging applications, helping align TNO’s scientific capabilities with evolving pharmaceutical research needs.
Please get in touch to discuss your preclinical ADME challenges, explore tailored studies, or identify opportunities to jointly develop and apply new research models.
Relevant links:
- Highly translational preclinical ADME models
- A higher throughput and physiologically relevant two-compartmental human ex vivo intestinal tissue system for studying gastrointestinal processes - ScienceDirect
- TNO-2019-intestinal.pdf (pdf)
- Organ-on-a-Chip offers more accurate preclinical studies
- Drug development accelerated with ex vivo gut-liver-kidney model